How plant compounds could target Alzheimer’s disease from multiple angles

By Vijay Kumar MalesuReviewed by Susha Cheriyedath, M.Sc.Aug 31 2025

Scientists reveal how plant-based compounds may combat Alzheimer’s through multi-target actions, but poor bioavailability and the blood-brain barrier limit the way dietary hope can be translated into real therapies.

Review: Polyphenols and Alzheimer's Disease: A Review on Molecular and Therapeutic Insights With In Silico Support

In a recent review published in the journal Food Science & Nutrition, researchers synthesized evidence on how dietary polyphenols modulate Alzheimer’s disease (AD) biology and evaluated mechanistic, computational, and translational insights.

Background

More than 50 million people worldwide are currently living with dementia, with numbers projected to rise substantially in the coming decades.

AD, the leading cause of dementia, features amyloid-beta (Aβ) plaques, tau tangles, oxidative stress, and neuroinflammation that gradually erode memory and independence.

Interest in polyphenols from fruits, vegetables, tea, coffee, and wine has grown because many people hope that everyday foods can support brain health. People also want to know whether these plant compounds can truly change disease biology, not just symptoms. 

By understanding the antioxidant, anti-inflammatory, and amyloid-modulating actions of these compounds, clinicians and consumers can make more informed choices about their diet and potential therapies. Current treatments are limited, which increases the demand for safe and accessible options. 

Further research is needed to turn these promising mechanisms into dependable, patient-centered benefits.

Pathology And Why Polyphenols Matter?

AD is a progressive neurodegenerative disorder in which Aβ peptides accumulate as plaques, microtubule-associated protein tau becomes hyperphosphorylated, and neurons are injured by reactive oxygen species (ROS) and persistent immune activation. These connected processes weaken synapses and cognition over time so that a little forgetfulness can grow into lost names, unpaid bills, and eventually complete dependency.

Polyphenols, plant phytochemicals that include flavonoids, phenolic acids, stilbenes, and lignans, are abundant in common foods and drinks, and they draw attention because they show antioxidant, anti-inflammatory, and amyloid-modulating actions that align with core features of Alzheimer’s biology.

Preclinical studies of resveratrol, curcumin, and epigallocatechin gallate (EGCG) have reported improved cognition and reduced neurodegeneration in models, suggesting that dietary patterns and nutraceuticals may complement medical care rather than replace it.

Together, these signals support a translational focus on how polyphenols act across oxidative stress, neuroinflammation, and protein aggregation, as well as on how such actions might be applied in clinical practice.

Mechanistic Actions: Oxidative Stress and Redox Signaling

Oxidative stress is a core driver of neuronal injury in AD. Polyphenols such as EGCG, resveratrol, quercetin, and curcumin enhance endogenous defenses by activating nuclear factor erythroid 2 2-related factor 2 (Nrf2) and temper pro-oxidant cascades regulated by nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinase (MAPK).

In experimental models, EGCG increases superoxide dismutase, catalase, and glutathione peroxidase, promotes Nrf2 nuclear translocation, and induces heme oxygenase-1 (HO-1) and NAD(P)H:quinone oxidoreductase 1 (NQO1), which together mitigate ROS damage and support cognitive function. 

Resveratrol similarly attenuates NF-κB-mediated signaling, reducing interleukin-1β (IL-1β) and tumor necrosis factor-alpha (TNF-α). Quercetin, on the other hand, exerts dual actions—activating Nrf2 and inhibiting MAPK, to prevent oxidative stress-induced apoptosis. 

These concerted effects make polyphenols more than simple radical scavengers; they act as network modulators that recalibrate redox homeostasis in vulnerable neurons.

Mechanistic Actions: Neuroinflammation and Glial Modulation

Activated microglia and astrocytes release cytokines and chemokines that amplify synaptic loss. Polyphenols counter this response by inhibiting NF-κB and MAPK signaling, thereby lowering inducible nitric oxide synthase and cyclooxygenase-2 and curbing inflammatory cascades.

Resveratrol suppresses microglial activation and decreases the expression of IL-1β and TNF-α; curcumin limits NF-κB translocation by preserving the inhibitor of kappa B (IκB). By shifting the glial environment toward resolution rather than attack, polyphenols preserve synapses and support plasticity that underpins learning and daily function.

In Silico and Multi-Target Evidence

Computational biology strengthens the mechanistic case by showing how polyphenols may bind proteins that drive AD. Molecular docking and molecular dynamics simulations indicate interactions with beta-secretase 1 (BACE1), acetylcholinesterase (AChE), tau, and glycogen synthase kinase-3 beta (GSK3-β), a kinase that promotes tau hyperphosphorylation.

In the present review, myricetin, luteolin, kaempferol, caffeic acid, quercetin, apigenin, curcumin, and ferulic acid exhibited strong predicted binding to GSK3-β, with docking scores from approximately −11.8 to −8.7 kcal/mol and recurring contacts at residues such as VAL A:135 and ASN A:64, stabilizing inactive conformations and implying a route to reduce tangle formation.

Related analyses note marine-derived compounds that inhibit AChE and BACE1 while modulating NF-κB, underscoring a multi-target strategy. Such in silico evidence does not replace validation, but it accelerates candidate selection and analog design, focusing scarce trial resources on scaffolds that are most likely to modify the disease.

Bioavailability, Blood-Brain Barrier, and Delivery

Promise meets pragmatism at the pharmacokinetic bottleneck: many polyphenols have poor bioavailability and limited blood-brain barrier (BBB) penetration. Rapid metabolism and low central exposure can blunt otherwise potent mechanisms.

Advances in drug delivery, including the use of nanoparticles, liposomes, and prodrugs, aim to enhance stability, improve transport, and increase brain uptake, while medicinal chemistry tailors lipophilicity and target engagement. 

The review also notes that inter-individual gut microbiota variability can influence polyphenol metabolism and brain-active metabolite profiles. However, this remains a secondary limitation compared with bioavailability and BBB challenges. These strategies aim to translate bench signals into clinically meaningful effects without compromising safety.

From Bench to Breakfast Table

Because polyphenols are found in daily diets in foods like berries, apples, onions, green tea, coffee, and olive oil, the science relates to grocery choices.

Diets inspired by Mediterranean or Mediterranean–DASH Intervention for Neurodegenerative Delay (MIND) patterns, combined with exercise and social engagement, are associated with lower oxidative stress and inflammation, and may help slow cognitive decline, providing families with practical steps while research advances.

Safety, Complementarity, And Equity

Polyphenols are not stand-alone cures: AChE inhibitors and N-methyl-D-aspartate receptor antagonists remain foundational for symptom management, and monoclonal antibodies targeting Aβ have sparked debate over their benefits and risks.

A realistic path blends lifestyle measures, symptomatic drugs, and polyphenol-rich patterns, with trials testing add-on effects and standardized dosing. Guidance should respect cultural cuisines and budgets, ensuring that brain-healthy actions are feasible for all in routine clinical care.

Conclusions

This review characterizes how polyphenols can address AD through antioxidant, anti-inflammatory, and multi-target actions that intersect with Aβ, tau, and redox biology.

Preclinical and in silico evidence support the activation of Nrf2, the restraint of NF-κB and MAPK, and the engagement of BACE1, AChE, and GSK3-β. Yet bioavailability and BBB limits temper promise. 

Going forward, trials, standardized formulations, and delivery systems that enhance brain exposure are essential to translating bench insights into benefits that matter to patients and their families.